<DOC>
	<DOCNO>NCT02487017</DOCNO>
	<brief_summary>Evaluation DC-CIK cell combine TACE treatment HCC</brief_summary>
	<brief_title>DC-CIK Combined With TACE Treatment Hepatocellular Carcinoma</brief_title>
	<detailed_description>60 patient Hepatocellular Carcinoma , receive Transcatheter Arterial Chemoembolization ( TACE ) , randomly divide group A ( receive DC-CIK+ TACE treatment ) group B ( receive TACE ) , randomize ratio 1:1 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<criteria>1880 year old ; Histologically confirm Hepatocellular Carcinoma stage III ; Patients accept Transcatheter Arterial Chemoembolization ; Patients life expectancy least 3 month ; Patients ChildPugh : A/B ; .Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . White blood cell ＜3 x 10^9/L , Platelet count ＜75 x 10^9/L ; BUN Cr normal limit 3.0 time ; Known suspect allergy investigational agent agent give association trial ; Pregnant lactating patient ; Known history Human Immunodeficiency Virus ( HIV ) , Hepatitis C Virus ( HCV ) TreponemaPallidun ( TP ) infection ; Patients suffer serious autoimmune disease ; Patients use long time use immunosuppressant ; Patients active infection ; Prior use anticancer treatment 30 day ; Now recently join another experimental clinical study ; History organ allograft ; Other situation researcher consider unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>